None listed
Conditions
Interventions
Intervention1: P3914: Part A:
P3914 50 at doses of 50 mg (1 x 50 mg tablet) to 3000 mg (12 x 250 mg tablet) will be administered orally in sitting posture with 240mL of drinking water followed by thor
Sponsors
Piramal Life Sciences Limited
Eligibility
Inclusion criteria
Inclusion criteria: for Part A, Part B & Part C 1.Male subjects aged between 18 and 45 years (including both) with Body Mass Index between 18 to 25 kg/m2 (including both). 2.Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable normal range. 3.Subjects having clinically acceptable 12-lead electrocardiogram (ECG). 4.Subjects having clinically acceptable X-Ray chest (P/A view). 5.Subjects having clinically acceptable endoscopy. 6.Have a negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine). 7.Have negative alcohol breath test. 8.Subjects willing to adhere to the protocol requirements and to provide written informed consent. For Part D Patients with acute postoperative dental pain (at least moderate in severity or score of 40 mm on VAS) after removal of an impacted third mandibular molar will be selected for study participation, if they meet the following criteria: 1.Male patients aged between 18 and 60 years (including both). 2.Patients with acute postoperative dental pain (at least moderate in severity or score of 40 mm on Visual Analogue Scale) 3.Patients with otherwise normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable normal range. 4.Patients having clinically acceptable 12-lead electrocardiogram (ECG). 5.Patients having clinically acceptable chest X-Ray (P/A view). 6.Patients having clinically acceptable endoscopy. 7.Have a negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine). 8.Have negative alcohol breath test. 9.Patients willing to adhere to the protocol requirements and to provide written informed consent.
Exclusion criteria
Exclusion criteria: for Part A, Part B & Part C 1.Hypersensitivity to NSAIDs or nitrodonating drugs. 2.History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder. 3.Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within one month of the study starting. 4.History or presence of significant gastric and/or duodenal ulceration including the last three months or gastroduodenal bleeding including the last six months prior to the screening visit. 5.History of peptic ulceration or significant dyspepsia as judged by the investigator. 6.Endoscopy finding of gastric or duodenal ulcer at baseline. Erosive esophagitis or other endoscopic appearance that constitutes a risk to the subject, if included in the study, as judged by the investigator. 7.Have positive test for Helicobacter pylori infection. 8.Orthostatic hypotension with a systolic blood pressure drop of ¡Ý 25 mm Hg and/or a diastolic blood pressure drop of ¡Ý 15 mm Hg within 5 minutes of standing when changing from supine to erect position. 9.A history of renal impairment, or a glomerular filtration rate (GFR) 60 mL/min or, at visit 1, a serum creatinine value 140 mol/L. 10.Use of aspirin, H2 antagonists, antacids, misoprostol, proton pump inhibitors, sucralfate including two weeks prior to the screening visit. 11.Subjects currently taking sildenafil, anticoagulants or ticlopidine, nitrates, nitrovasodilating drugs (e.g. nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, glycerin trinitrate), diuretics (in a dose potentially leading to volume depletion). 12.Use of any prescribed medication during last two weeks or OTC medicinal products (including herbal/traditional medicine preparations) during the last one week prior to initiation of study. 13.History or presence of significant alcoholism or drug abuse in the past one year. 14.Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C. 15.History or presence of smoking or use of other tobacco, pan, gutkha products since last six months. 16.History or presence of significant asthma, urticaria or other allergic reactions. 17.History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumour. 18.Difficulty in swallowing solids like tablets or capsules. 19.History or presence of cancer. 20.Difficulty with donating blood. 21.Major illness during three months before screening. 22.Participation in a drug research study within past three months. 23.Donation of blood in the past three months before screening. For Part D 1.Hypersensitivity to NSAIDs or nitrodonating drugs. 2.History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder. 3.Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month of the study starting. 4.History or presence of significant gastric and/or duodenal ulceration including the last three months or gastroduodenal bleeding including the last six months prior to the screening visit. 5.History of pept
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety, tolerability of P3914Timepoint: Part A:At 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96 and 120 hrs after dosing. Part-B: At pre-dose (within 30 min of dosing) on Day 2 to Day 13, pre dose (within 30 min of dosing) and at 4 and 12 hrs post-dose on Days 1 and 14. Part-C: At pre-dose (within 30 min of dosing) and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96 and 120 hrs after dosing in each period. Part:d At pre-dose (within 30 min of dosing) and at 0.5, 1, 2, 4, and 8 hrs after dosing. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean pain intensity differenceTimepoint: NA;Time to first perceptible pain reliefTimepoint: At the start of pain;Time to meaningful pain reliefTimepoint: up to a maximum of 8 hrs after dosing | — |
Countries
India
Contacts
Public ContactDr Sujay Kulkarni
Piramal Life Sciences Limited
Outcome results
None listed